Listen Get

The Loving Takeover

Author
Affiliation

Mike P. Sinn

International Campaign to End War and Disease

Abstract

The Western military-industrial complex has a combined market capitalization of approximately $670 billion across the major US primes, plus another $131 billion across allied European primes. A majority shareholding requires roughly $400 billion nominal before any acquisition premium, disclosure friction, or transaction cost. Distributed across the global population, the per-person ante is approximately $90. Once humanity holds the majority, the single most powerful action is to redirect the ~$127 million per year of military lobbying toward the 1% treaty. Expected total value per global human: ~6,000x-22,000x the contribution at base case (mostly welfare value, not cash); ~60x-220x even after a 99% pessimistic haircut. The takeover is structurally loving: existing shareholders may benefit from a better long-term corporate strategy, military-contractor employees keep their jobs (and gain new ones in the medical pivot), and the directors and officers who settle gain personal life expectancy alongside everyone else.

Keywords

loving takeover, friendly takeover, shareholder coalition, military industrial complex, military contractors, 1% treaty, coordinated share purchase, lobbying redirection

STATUS: DRAFT. Requires securities, antitrust, and CFIUS counsel review before any organized buy-up begins. Market-cap numbers are approximate and should be re-verified against current 10-K filings before publication.

COST TO BUY CONTROL OF THE WESTERN MILITARY-INDUSTRIAL COMPLEX: approximately $873 billion realistic, or ~$109 (95% CI: $107-$111) per global human.

ANNUAL LOBBYING BUDGET YOU GET TO REDIRECT: $198 million (95% CI: $190 million-$210 million), not yet pointed at the 1% treaty167 168. After the takeover, it is.

EXPECTED VALUE PER GLOBAL HUMAN PARTICIPANT: ~$530,000-$2,000,000 in total expected value at base case (~6,000x-22,000x the contribution; mostly welfare value, not cash). Even after a 99% pessimism haircut, ~$5,000-$20,000 in expected total value per $109 (95% CI: $107-$111) contributed.

This is the lawsuit escalated. The lawsuit is the cheap side path: own one share, send the board a love letter (the law calls it a legal letter the board is required to read), and the board is required to read the math. The Fund is the main version: pool capital, own enough shares to matter, and make the best lobbyists money can buy start working on keeping their shareholders alive.

Why “Loving,” Not “Hostile”

A normal hostile takeover is hostile to the people being acquired. The acquirer pays as little as possible. The existing shareholders get cashed out at a small premium. The directors and officers usually lose their jobs. The acquired company is restructured against the prior management’s wishes.

This takeover does the opposite of all four.

  1. Existing shareholders are not the enemy. The campaign is built around the claim that the companies are worth more under a better long-term strategy: same engineering base, same federal customer, fewer self-defeating lobbying objectives, and a larger economy to sell into. Existing shareholders are not asked to donate value. They are asked to consider the better trade.
  2. Military-contractor employees keep their jobs. The companies are not liquidated. The engineering workforce is redirected toward medical, biotech, and dual-use civilian applications that compound at higher rates in the post-treaty economy. Headcount goes up, not down.
  3. Directors and officers gain personal life expectancy. The settlement adds approximately 12 years (95% CI: 8 years-18 years) to the average beneficiary’s healthy life, including the directors and officers themselves and their families. The same directors who currently face the same age-stratified disease risk as everyone else gain measurable additional years of life from the company they direct settling rather than fighting.
  4. The acquirers are everyone. The campaign has no central acquirer extracting value at the expense of others. The control premium, if one is paid, is paid to existing shareholders. Later participants capture the policy benefits. Military contractors capture an addressable market roughly 1.43x (95% CI: 1.22x-1.56x) larger than the current trajectory at year 15. The structure is designed so the people being acquired are also beneficiaries of the acquisition.

The only thing the takeover changes is a budget line item: the $198 million (95% CI: $190 million-$210 million)/year of lobbying that is not yet directed at the 1% treaty. The humans associated with that line item are not the problem. The direction is.

Why Buying Shares Is Selfishly Rational

The campaign does not require altruism. It requires self-interest correctly calculated.

A military contractor’s share price today reflects its current business model: sell weapons, lobby for more weapons spending, repeat. If the campaign succeeds, two things happen mechanically:

  1. The addressable market grows. Under the treaty trajectory, GDP at year 15 is roughly 1.43x (95% CI: 1.22x-1.56x) the current trajectory. Even if military spending stays at the same fraction of GDP, the absolute military budget grows in proportion. A military contractor operating in a bigger economy captures proportionally more absolute revenue, with no change in its market share.
  2. The pivot opportunity opens. Military engineering talent applied to medical, biotech, AI-augmented drug discovery, decentralized FDA169,170 infrastructure, sensors, imaging, materials, and dual-use civilian applications compounds at substantially higher rates than current cost-plus military work. The same workforce produces more value per engineer-year in the medical pivot than in the weapons-system status quo.

The lopsided upside. If the campaign succeeds, military contractor shares appreciate substantially through both channels above. If the campaign fails, the shares stay roughly where they are (a normal military contractor position). The downside is the foregone return on whatever the share purchase displaced (typically index funds at ~7-10% annualized).

The credibility cascade. As the campaign builds credibility, the market may begin to price in a higher probability that the thesis works. The lawsuit (and the legal-letter pipeline it sits inside) is the catalyst that activates this cycle: every legal letter filed, every board response received, every press article covering the math is a credibility-step that shifts probability mass toward “campaign succeeds.”

This is not speculation. It is the same way any value-event gets priced into a stock: M&A announcements, FDA approvals, regulatory rulings, earnings revisions. The campaign supplies the value-event (a structural shift in the military contractor’s long-term addressable market and pivot optionality) and the market prices it in as the probability of success rises.

THE FLYWHEEL: THREE LOOPS, ONE MACHINE

   HUMANITY BUYS MILITARY CONTRACTOR SHARES
   (~$109 (95% CI: $107-$111) per human buys all of them)
        |
        v
   CREDIBILITY RISES
        |        \
        |         more shareholders read the analysis
        |         [LOOP A: the board pressure improves]
        v
   BOARD CONTROL ACCUMULATES
        |
        v
   LOBBYING REDIRECTED TO THE 1% TREATY
   ($198 million (95% CI: $190 million-$210 million)/year changes sides)
        |
        v
   TREATY PASSES  ($27.2 billion/year, forever)
        |        \
        |         bondholders collect
        |         $2.72 billion/year, and the
        |         investor lobby pushes for 2%, then 5%
        |         [LOOP B: the lobbying gets stronger]
        v
   CLINICAL TRIALS FUNDED
   ($21.8 billion/year, 80% of every treaty dollar)
        |
        v
   DISEASES START FALLING
        |
        v
   ECONOMY GROWS
   (1.43x (95% CI: 1.22x-1.56x) the current path at year 15)
        |
        \--> the big military contractors have a better long-term market
             [LOOP C: the shareholder case improves]

Three reinforcing loops, one machine. Each lap makes the next lap cheaper.

Selfish and altruistic converge. A reader who does not care about disease eradication and wants only to make money has the same correct action as a reader who cares about disease eradication and would buy the shares purely to redirect the lobbying. Both buy the shares. The campaign requires no shared motivation, only shared action.

Market-Impact and Compliance Boundary

Large acquisition programs can affect price, trigger disclosure obligations, and attract regulatory scrutiny. This chapter is not a trading campaign, a recommendation to coordinate purchases, or a model of short-term price impact.

The public thesis is narrower and cleaner: disclosed, long-horizon shareholders can use ordinary shareholder tools to ask whether military-contractor lobbying maximizes long-term shareholder value. Any organized acquisition vehicle, campaign to put your own people on the board, or large ownership program requires securities, antitrust, CFIUS, and proxy-solicitation review before it moves from analysis to action.

Why This Works

The military-industrial complex is not a sovereign power. It is a collection of publicly traded corporations whose shares are for sale to anyone with a brokerage account. The lobby that has driven military budget expansion for eighty years is a line item in those corporations’ SG&A. The line item is controllable by whoever holds the board. The board is electable by whoever holds 50%+1 of the shares. The shares are for sale.

Stated as a chain: the diseases that will kill you and your family stay in the trial queue because the trials are not funded. The trials are not funded because the federal budget pays for missiles instead of cures. The federal budget pays for missiles instead of cures because the military lobby tells Congress to. The military lobby tells Congress to because the military contractors authorize and pay for it. The military contractors authorize and pay for it because their boards vote to. The boards vote to because their shareholders elect them. The shareholders elect them because nobody has yet pointed out that they could elect a different board for the price of a coffee per global human.

This page points it out.

The Math

Major Western military contractors (approximate market caps)

Contractor Ticker Approx market cap 50%+1 control cost
RTX (Raytheon) RTX ~$160B ~$80B
Boeing BA ~$130B ~$65B
Lockheed Martin LMT ~$110B ~$55B
General Dynamics GD ~$80B ~$40B
Northrop Grumman NOC ~$75B ~$38B
L3Harris LHX ~$45B ~$23B
Leidos LDOS ~$20B ~$10B
Booz Allen Hamilton BAH ~$20B ~$10B
CACI International CACI ~$11B ~$6B
Huntington Ingalls HII ~$10B ~$5B
SAIC SAIC ~$8B ~$4B
US primes subtotal ~$670B ~$336B
BAE Systems (UK) BA.L ~$76B ~$38B
Thales (France) HO.PA ~$55B ~$28B
Allied primes ~$131B ~$66B
Total Western primes ~$801B ~$401B

Numbers are approximate and require verification against current filings before any campaign acts on them.

Realistic cost after acquisition premium

Acquiring influence at this scale would not happen at the last quoted market price. Any real acquisition program has to budget for premium, timing, disclosure, execution friction, and legal review. Realistic effective cost after a 1.8x (95% CI: 1.5x-3x) acquisition premium:

  • Nominal: ~$401 billion
  • Realistic with acquisition premium: $873 billion

The premium is part of the capital required to buy influence at scale. It is not a promise of trading profit.

Per-person cost

Cost distributed across Per-person cost (realistic)
Global humans (8 billion) ~$109 (95% CI: $107-$111)
Global adults (~5.5 billion) ~$130
Global middle class+ (~3.5 billion) ~$200
US adults (260 million) ~$2,700
US households (130 million) ~$5,400
US households earning >$100k (~50 million) ~$14,000

The entire Western military-industrial lobbying apparatus can be brought under common shareholder control for less than the price of a coffee per week per global human for a single year.

This number is calculable. It is not a fantasy.

How much you actually need

$873 billion is the price of certainty, not the price of victory. It is what it costs to own 50.1% and need nobody’s agreement. Board control usually arrives much earlier:

Tier Stake What it gets you
One share (~$200) A letter the board is obliged to read The lawsuit campaign
A fraction of a percent, plus a campaign to put your own people on the board Board seats, if the financial case persuades the index funds Engine No. 1 won three ExxonMobil seats with 0.02% of the shares
1-5% across the primes Agenda-setting positions at every annual meeting The activist tier
50.1% Nobody has to agree with you

$873 billion

Three institutional investors hold 60-75% of every big military contractor, and their job is to vote for whatever makes the shares worth more. The pitch to them is the one this chapter already made: the treaty makes the companies more valuable. Each tier is insurance against the cheaper tier failing. You climb only as far as the persuasion fails.

What Humanity Does Once It Owns the Companies

Ranked by impact. The first action is the entire game; the rest are bonus.

Tier 1: Redirect the lobbying budget (highest impact, zero cost)

Military contractors currently spend $198 million (95% CI: $190 million-$210 million) per year lobbying Congress to expand military appropriations. This is the most effective political-influence operation on Earth. It has driven US military spending from its 1939 baseline to current levels and prevented every serious proposal for reallocation.

After the takeover, the same budget is reallocated to lobby for the 1% treaty. Same lobbyists. Same senators. Same lunches. The only difference is that the murder-money machine starts asking for medicine money.

Cost: $0 (it is the same line item, just relabeled).

Time to effect: Immediate. The first quarter’s lobbying disclosures will show the new direction.

Why this is the entire game: US military and foreign policy follows military-industry lobbying with high fidelity. Flip the lobby, and the senators who depend on military PAC money to keep their seats follow within one election cycle. China and Russia become the only remaining holdouts, and they are easier holdouts to address with the US lobby championing the treaty than with the US lobby blocking it.

Tier 2: Public corporate endorsement

Every major military contractor publicly endorses the 1% treaty. The most common political argument against the treaty (“industry opposes it”) evaporates overnight. Senators lose cover. Editorial boards reverse positions. The Overton window shifts by a decade in a week.

Cost: $0.

Time to effect: One press release per contractor.

Tier 3: Stop opposing donations

Military PACs currently donate to candidates who oppose the treaty. After the takeover, those donations stop. They can also reverse direction: donate to candidates who support the treaty. Per cycle this redirects roughly $30-50 million across all military PACs.

Cost: $0 (reallocates existing political spending).

Time to effect: Next election cycle.

Tier 4: Shareholder resolutions requiring ROI analysis of all lobbying

Every shareholder meeting requires the board to publish a policy-return analysis of the lobbying budget: current objective versus the 1% treaty versus pragmatic clinical trials versus any alternative the Optimal Policy Generator171 ranks higher.

The new analyses will reach the conclusion the demand letters have been forcing all along: lobbying for military expansion produces negative ROI for shareholders because it suppresses the GDP growth that funds the company’s addressable market. The analysis becomes auditable documentation that locks in the new lobbying direction against backsliding.

Cost: Negligible (corporate audit work).

Time to effect: Next AGM, typically 3-9 months.

Tier 5: Pivot R&D toward medical and biotech applications

Military contractors already produce technologies with direct medical applications: imaging, sensors, materials, AI, robotics, encryption. R&D budgets can be partially redirected toward decentralized FDA169,170 infrastructure, AI-augmented drug discovery, and clinical trial logistics. The existing engineering workforce is well suited to this pivot; many of these companies already have biotech-adjacent product lines.

Cost: Capital reallocation, no new spending required.

Time to effect: 1-3 years for substantial product impact.

Tier 6: Cancel weapons systems with no defensive justification

Some military programs have negative externalities exceeding their revenue (autonomous weapons, cluster munitions, certain export-only programs). The board can wind these down without compromising the company’s military product lines.

Cost: Negative (eliminates loss-making or marginal programs).

Time to effect: 1-3 years.

Tier 7: Open-source military IP for medical use

Patents on technologies with dual-use applications (imaging, sensors, AI models, materials, manufacturing processes) can be licensed for free for medical applications. This accelerates DFDA infrastructure and drug discovery without requiring active R&D pivot.

Cost: Foregone licensing revenue, typically small relative to the medical impact.

Time to effect: 6-12 months.

Tier 8: Partial manufacturing conversion to medical devices and vaccines

Military factories have precision manufacturing, supply chain, and quality systems that translate well to medical device and vaccine production. Reverse-WW2 industrial mobilization: instead of converting consumer factories to military, convert military to consumer and medical.

Cost: Capex investment, typically pays back within 5-7 years.

Time to effect: 3-5 years.

Tier 9: Distribute dividends directly to the 8 billion shareholders

Military contractor profits historically flow to a narrow set of institutional and high-net-worth shareholders. After the takeover, profits flow to the 8 billion humans who own the shares. Per-capita this is small (~$10-50 per global human per year) but it is the first direct income transfer from the military industrial complex to humanity in history.

Cost: Negative (just redistributes existing profits).

Time to effect: Next dividend declaration.

Expected Value Per Person

A note on what these numbers are. The totals below are total value to you as a human: they add the financial return on your shares to the welfare value of the extra years of life and health the plan buys you, valued at standard QALY and statistical-life rates. Most of the total is that welfare value, not cash in your account. If you want the financial equity return on its own, modeled against the historical track record of taking over badly-run companies (Buffett, the activist literature, the governance evidence) with a floored downside, that is in Investment Terms. The two are different objects. Do not hand a skeptic the welfare multiple and call it a stock return.

Investment per person (realistic, including acquisition premium)

Population Cost
Per global human ~$109 (95% CI: $107-$111)
Per US adult ~$2,700
Per US household ~$5,400

Expected return per person (base case, treaty passes and multipliers hold)

For a global human contributing ~$109 (95% CI: $107-$111):

Benefit Approx value per person
Lifetime income gain from the treaty trajectory ~$518,879 (95% CI: $221,703-$860,930)
Disease eradication value: ~12 years (95% CI: 8 years-18 years) of extra healthy life × global value per healthy life-year (~$30-50K/year) ~$360,000-$600,000
Lower lifetime apocalypse risk ~$1,000-$10,000
Military-contractor dividends now flowing to humanity ~$10-50/year ongoing
Total EV per global human (base case) ~$530,000-$2,000,000

Base case ROI multiple per global human: ~6,000x to 22,000x.

For a US adult contributing ~$2,700:

Benefit Approx value per person
Personal net-worth gain at year 15 (US median net worth ~$190K, economy at 1.43x (95% CI: 1.22x-1.56x) the current trajectory) ~$40,000-$140,000
Disease eradication: ~12 years (95% CI: 8 years-18 years) of extra healthy life × US QALY threshold ($100,000/year) ~$800,000-$1,800,000
Lower lifetime apocalypse risk ~$10,000-$100,000
Direct military-industry dividends ~$500-$2,000/year ongoing
Total EV per US adult (base case) ~$850,000-$2,100,000

Base case ROI multiple per US adult: ~300x to 800x.

Pessimism-adjusted expected value

Apply a 99% pessimism haircut to every line item above (treaty fails to pass, multipliers are wrong, takeover is partially blocked, implementation is incomplete, etc.):

Population Discounted EV Discounted ROI
Global human (~$109 (95% CI: $107-$111) in) ~$5,000-$20,000 ~60x-220x
US adult (~$2,700 in) ~$8,500-$21,000 ~3x-8x

Even with a 99% haircut, the expected total value remains roughly 60x-220x the contribution. Most of that is welfare value (extra healthy life-years at standard rates), not cash; the financial-only return is modeled in Investment Terms.

How It Finances Itself (Not a Bonfire)

The numbers above are the price if you paid all cash and then set the money on fire. You would do neither.

Start with the cash. Military contractor cash flows are about as steady as cash flows get, which is precisely what lets you borrow against them. A leveraged buyout of something this stable can carry 50% to 65% debt, so taking a company private costs an equity slice, not the whole sticker. The acquisition premium pushes the price up and the borrowed money pushes the cash-down requirement back down; they roughly cancel. You need an equity check, plus debt the company itself carries.

Then comes the good objection: if the debt is serviced by the company’s cash flows, and you are redirecting the company, do you not strangle the thing you just bought? In today’s world, yes. That is the trap.

But you are not redirecting these companies into a desert. You are redirecting them into a market the plan itself irrigates. Today a company pays for its own efficacy trials, which are the majority of the cost of a drug, and then waits a decade to see a dollar back. That decade-long hole is what would eat the debt. The Right to Trial Act172 and the decentralized FDA169,170 fill it: the public trial fund pays for the efficacy component, the dFDA makes each trial roughly 44.1x (95% CI: 12.8x-210x) cheaper, and anyone may join any trial. The company’s single largest expense stops being an expense and becomes a funded revenue line. It is cash-flow positive on the new model almost at once. There is no decade to bridge.

And the competence transfers exactly. These firms are not good at “weapons.” They are good at winning government-funded R&D contracts, integrating complex systems, and lobbying. Point that skill at the health-security market the treaty creates and it is the same skill in a new costume. The lobbying you redirect passes the treaty; the treaty funds the trials; the trials are the contracts these companies win. The snake eats its own tail in the one direction where that is a good thing.

So this is not capital poured into a hole. It is capital redeployed into a government-funded growth sector that the redeployment itself calls into being. The redirected company is worth more, not less, which is the entire reason the debt is serviceable and the early shareholders get richer on the way in. Lenders finance growth pivots. They do not finance bonfires. This is the former wearing the costume of the latter.

Real Frictions

These are real, and they shape how the campaign is structured. They do not eliminate it.

Acquisition compliance

Military contractor stock floats are not infinitely liquid. A large acquisition program has to assume price impact, filing obligations, and legal scrutiny. The modeled premium is 1.8x (95% CI: 1.5x-3x) for acquisition planning, not a public trading target.

Mitigation: counsel-led structure, disclosure planning, beneficial-ownership monitoring, proxy-solicitation review, CFIUS analysis, and public communication of the long-term shareholder objective rather than any short-term trading outcome.

CFIUS and national security review

Any large or unusual ownership change in a major US military contractor triggers Committee on Foreign Investment in the United States review. A coalition of US citizens buying shares is domestic and falls outside CFIUS, but the Department of Defense has informal mechanisms to slow or block ownership changes it considers adversarial to national security. This is a real obstacle, not a fatal one.

Mitigation: CFIUS reviews substance: domestic ownership, disclosed intent, no foreign control, and classified programs left under existing cleared management. The campaign has all four. The presentation’s job is to make that substance legible.

The deeper argument runs the other way. The current base is itself the national-security problem: it rewards competence in lobbying over competence in production, which is how a system spending close to a trillion dollars a year still cannot surge artillery shells and has failed its audit every year it has been tried. A takeover that turns these companies from buyers of influence back into builders of things, and stands up a health-security industrial base alongside the military one, is the pro-security move, not the adversarial one. The single piece to keep off the table is the weapons themselves: the actual munitions and classified programs stay under existing cleared control. Humanity votes on the lobbying and the capital allocation. It does not vote on the nuclear codes.

Staggered boards and poison pills

Most big military contractors have anti-takeover provisions that delay control even with majority ownership. Staggered boards can be replaced only one-third per year. Poison pills can dilute acquirers the board deems hostile.

Mitigation: Practical control takes 2-3 years post-acquisition rather than immediate. Shareholder resolutions and demand letters operate in parallel during the transition period and produce most of the lobbying-redirection benefit before formal board control is achieved. The “loving” framing also matters here: poison pills are designed to deter acquirers who plan to extract value at the expense of existing shareholders. They are harder to justify against an acquirer mathematically demonstrating that existing shareholders are richer under the takeover than under the status quo.

Coordination capacity

Buying half the float of every big Western military contractor requires coordinating millions of purchasers. This is a real operational challenge, though not the corporate-campaign kind. It is closer to the chain-letter or viral-meme kind: distributed, opt-in, low-friction per participant.

Mitigation: A standardized acquisition vehicle (e.g., an index fund or trust dedicated to the takeover) that anyone can buy into for the price of one share. Open-source coordination of which contractors are being targeted in which quarter. The same recruitment funnel as the shirts campaign and the lawsuit campaign.

“But They’ll Lose Their Government Contracts”

This is the objection that sounds serious. It is not.

The objection goes: if a shareholder coalition takes over military companies and redirects their lobbying, the government will punish them by canceling their contracts. The companies go bankrupt. You bought an expensive pile of nothing. Congratulations.

The problem with this objection is that it assumes the Pentagon has options. It does not.

Huntington Ingalls Industries is the sole builder of nuclear aircraft carriers on planet Earth. There is no backup aircraft carrier factory. If the Pentagon cancels HII’s contract, the US Navy stops getting aircraft carriers. Not “gets them from someone else.” Stops getting them. Northrop Grumman is the sole builder of the B-21 Raider stealth bomber. General Dynamics is the sole builder of Columbia-class nuclear submarines. These are not competitive markets. They are monopolies, and the customer cannot leave.

The government does not contract with these companies because the companies lobby well. The government contracts with them because nobody else on the planet can build what they build. The lobbying wins marginal contracts, cost-plus expansions, and favorable terms on the next procurement cycle. It does not win the core work. The core work exists because a nuclear submarine requires roughly 10 million person-hours of specialized labor, and exactly one company has the workforce, the facilities, and the security clearances to deliver it.

So the real question is narrower than it sounds: does the marginal ROI on lobbying (winning the next cost-plus expansion) exceed the marginal ROI on diversification (pivoting that same money into health tech, renewable energy, AI-augmented drug discovery)? For a company operating in a post-treaty economy where GDP at year 15 is roughly 1.43x (95% CI: 1.22x-1.56x) larger, the diversification bet is obviously better. You are not choosing between revenue and no revenue. You are choosing between a slow-growth monopoly and a fast-growth monopoly that also has new product lines.

If this sounds theoretical, it has already happened. In 2021, a twelve-person hedge fund called Engine No. 1 won three board seats at ExxonMobil, one of the largest companies on Earth, on a platform of accelerating the energy transition. The stock did not crash. It went up. Shareholder activism that aligns a company with long-term secular trends makes the company more valuable, not less. The market is not confused about this. The market prices it in, which is why Engine No. 1’s investors made money.

The sole-supplier argument is not a reason the takeover fails. It is a reason the takeover is structurally safe. You are buying monopolies whose customers cannot leave, and redirecting their discretionary spending toward higher-return opportunities. The downside is “you own a monopoly military contractor.” The upside is “you own a monopoly military contractor that also does health tech in a substantially bigger economy.” This is not a hard trade.

Relationship to the Lawsuit Campaign

The two campaigns are complementary, not alternative.

Lawsuit Loving takeover
Cost per participant ~$200 (one share) ~$109 (95% CI: $107-$111) (proportional share of control)
Number of participants required Hundreds to thousands Millions to billions
Mechanism Force the math into boardrooms via demand letters Buy the board, change the lobbying direction
Time to effect 1-3 years 2-5 years
What it produces Public board responses, media coverage, Overton window shift Direct policy change via redirected lobbying
Failure mode Court dismisses, board ignores Buy-up incomplete, board partial control
Compounding effect on the other Demand letters become takeover groundwork Shareholder control becomes the venue where the demands get enacted

The lawsuit campaign generates the public attention and shareholder organization that makes the takeover financially feasible. The takeover, in turn, locks in the lawsuit’s asks against backsliding by ensuring the board itself supports the treaty. Run them together.

Relationship to Buying Politicians Directly

There is also the rent-versus-own question. You can buy the politicians directly: roughly $25.5 billion (95% CI: $17.5 billion-$36.3 billion) for the American set, $128 billion (95% CI: $71.7 billion-$206 billion) for the world’s. It works, but it is rent. The money is spent, the politicians need re-buying every election cycle, and the other side can outbid you at the next auction. Shares are different. If the campaign works, you own the machine that buys the politicians, permanently. If it never works, you still own the shares and whatever they gained along the way. Buying politicians is an expense. Buying their owners is an asset. This is why the more expensive path is the cheaper one.

Next Steps

This page is a draft. Before any campaign acts on the math:

  1. Verify market cap and float numbers against current 10-K filings.
  2. Engage securities and antitrust counsel on the structure of an aggregating acquisition vehicle.
  3. Engage CFIUS counsel on framing and review posture.
  4. Build the acquisition vehicle (index fund, trust, or DAO-style coordination) that allows distributed participation at $109 (95% CI: $107-$111) per share.
  5. Coordinate with the lawsuit campaign so demand letters and share accumulation reinforce each other.
  6. Coordinate with the handout and shirts campaign so recruitment of participants happens through the same funnel.

For the underlying argument for why this is necessary, see Where Am I Wrong? and the 1% treaty paper. For the liability framework that quantifies the harm the takeover is correcting, see Humanity v. Government.

Your Money, Your Choice

The entire plan on this page, stated once: buy the military contractors, use their lobbyists to give the money back to the people, let the people decide what to spend it on.

That is it. Everything else on this page is the math proving it works and the frictions slowing it down.

The redirected $198 million (95% CI: $190 million-$210 million) per year does not go to a committee. It does not go to a czar. It does not go to a panel of experts who will thoughtfully allocate it on your behalf while charging 40% overhead. It goes to a Wishocracy173: every person gets a proportional say in how the reallocated funds are spent, under real budget constraints, with tradeoffs visible. You want the money spent on cancer trials? Vote for cancer trials. Pandemic preparedness? Vote for that. You think the whole thing is stupid and the money should stay in military spending? Vote for military spending. The system does not care what you pick. It cares that you pick.

This is the part that breaks political objections, because every political tribe already wants this. They just describe it differently.

If you are conservative: this is smaller government. The money currently disappears into a military bureaucracy that has failed its own audit every single year it has been tried. Giving it back to the people who earned it and letting them choose is the most conservative fiscal policy available. Less bureaucracy, more accountability, your money back.

If you are progressive: this is direct democratic allocation of public resources to healthcare, education, climate, and poverty reduction. No intermediary. No lobbying. The people who need the services choose the services.

If you are libertarian: this is individual choice replacing government planning. Instead of 535 members of Congress deciding how to spend a trillion dollars, 330 million Americans decide how to spend their share. The mechanism is voluntary. The outcome is decentralized.

If you are religious: this is what “love thy neighbor” looks like when you write it into the budget. Your neighbor is dying of a disease that has a cure stuck in a trial queue. You take the money currently pointed at building the next missile and point it at finishing the trial. You do not need to use the word “love.” You just move the decimal point.

The closest thing to a loser is the roughly 2,000 people currently paid to keep the budget pointed at missiles: the members of Congress collecting military PAC contributions, and the lobbyists whose fees depend on the budget growing. The plan’s response to them is a raise. The lobbyists get a client with a bigger budget asking for medicine instead of missiles (same firms, same lunches, better wine). The politicians get the Senator Smith arithmetic: more campaign money and a better post-office career, for voting yes. The only way to lose under this arrangement is to be offered more money to stop helping kill people, and refuse. Some will refuse. That is a decision, not a casualty. The number of people who benefit is roughly 8 billion of people (95% CI: 7.8 billion of people-8.2 billion of people).

The Ledger

Every person with skin in the game, before and after. This is the no-adversaries claim in auditable form.

Who Status quo After the takeover
Existing shareholders Hold military contractor stock Same stock, repriced upward by the buy-up
Employees of the primes Build weapons on cost-plus Same desks plus the medical pivot; headcount up
Directors and officers The same disease risk as everyone ~12 years (95% CI: 8 years-18 years) of additional healthy life
Early buyers Hold cash Bought probability while it was cheap
Every other human The disease queue ~$518,879 (95% CI: $221,703-$860,930) in lifetime income, plus the healthy years to spend it
Pharma Casino: 90% failure on its own money Salary: trials become treaty-funded revenue
Insurers Pay chronic-disease claims forever Claims fall as cures land
Doctors Paid to argue with insurers Paid per trial participant
Soldiers Deployed to defend budget lines Same paycheck (99% of the budget stays), fewer occasions to die for it
Politicians who vote yes Military PAC money More money: campaign support now, a better career after
Lobbyists A $198 million (95% CI: $190 million-$210 million)/year client A richer client asking for medicine
Anyone who refuses the raise Paid to expand the budget Outbid and replaced. Self-inflicted.
The diseases 6,650 of them, operating freely Eradication queue, fully funded

The plan has exactly one structural adversary, and it is on the last row.

This is Wishocracy applied at its simplest: instead of the government deciding what you need, you decide what you need. The government’s track record on this question is a trillion dollars a year on missiles and zero dollars a year on the diseases that will probably kill you. Your track record on this question is that you would rather not die. The data favors your judgment.

The Funniness of This Loving Takeover, Mathematically

The financial ROI is obvious: ~$109 (95% CI: $107-$111) in, ~$530,000-$2,000,000 out. The financial ROI is also not the point. The point is that this is the funniest loving takeover in the universe, and the funniness is also calculable.

A normal hostile takeover produces one laugh: the laugh of the acquirer counting their gains. This one produces approximately 3.51 quadrillion laughs (95% CI: 971 trillion laughs-9.71 quadrillion laughs).

The chain:

The full calculation:

\[ \begin{gathered} L_{shirt} \\ = DALYs_{max} \times L_{year} \\ = 565B \times 6{,}200 \\ = 3510T \end{gathered} \]
where:
\[ \begin{gathered} DALYs_{max} \\ = DALYs_{global,ann} \times Pct_{avoid,DALY} \times T_{accel,max} \\ = 2.88B \times 92.6\% \times 212 \\ = 565B \end{gathered} \]
where:
\[ T_{accel,max} = T_{accel} + T_{lag} = 204 + 8.2 = 212 \]
where:
\[ \begin{gathered} T_{accel} \\ = T_{first,SQ} \times \left(1 - \frac{1}{k_{capacity}}\right) \\ = 222 \times \left(1 - \frac{1}{12.3}\right) \\ = 204 \end{gathered} \]
where:
\[ \begin{gathered} T_{first,SQ} \\ = T_{queue,SQ} \times 0.5 \\ = 443 \times 0.5 \\ = 222 \end{gathered} \]
where:
\[ \begin{gathered} T_{queue,SQ} \\ = \frac{N_{untreated}}{Treatments_{new,ann}} \\ = \frac{6{,}650}{15} \\ = 443 \end{gathered} \]
where:
\[ \begin{gathered} N_{untreated} \\ = N_{rare} \times 0.95 \\ = 7{,}000 \times 0.95 \\ = 6{,}650 \end{gathered} \]
where:
\[ \begin{gathered} k_{capacity} \\ = \frac{N_{fundable,ref}}{Slots_{curr}} \\ = \frac{23.4M}{1.9M} \\ = 12.3 \end{gathered} \]
where:
\[ \begin{gathered} N_{fundable,ref} \\ = \frac{Subsidies_{trial,ref}}{Cost_{pragmatic,pt}} \\ = \frac{\$21.8B}{\$929} \\ = 23.4M \end{gathered} \]
where:
\[ \begin{gathered} Subsidies_{trial,ref} \\ = Funding_{trial,ref} - OPEX_{trial} \\ = \$21.8B - \$40M \\ = \$21.8B \end{gathered} \]
where:
\[ \begin{gathered} OPEX_{trial} \\ = Cost_{platform} + Cost_{staff} + Cost_{infra} \\ + Cost_{regulatory} + Cost_{community} \\ = \$15M + \$10M + \$8M + \$5M + \$2M \\ = \$40M \end{gathered} \]
where:
\[ L_{year} = L_{day} \times 365 = 17 \times 365 = 6{,}200 \]

The ratio of laughs produced to laughs generated by a typical joke is approximately 3.51 quadrillion to 1. The ratio of laughs produced to the ~$109 (95% CI: $107-$111) per-human cost is approximately 39 trillion laughs per dollar. The cost-per-laugh is approximately $0.000000000000026.

Carl Linnaeus, Charles Darwin, and the entire history of biology never had a sample size large enough to measure a joke this funny. This page contains the first known calculation of a joke at quadrillion-laugh scale. The other contenders (the ozone treaty, the eradication of smallpox, the Marshall Plan) all produced fewer than 10^12 laughs each. This one produces more than 10^15.

Any remaining objection has to outweigh 3.51 quadrillion laughs.